Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing transformative medicines primarily in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Their mission is to address significant unmet medical needs and improve human health worldwide, with a particular focus on bringing innovative therapies to patients in China and beyond. Zai Lab leverages its own R&D capabilities as well as strategic collaborations with global biopharmaceutical leaders.
Serves as the principal executive office, overseeing global strategy, research and development, China operations, and corporate functions.
Located in Zhangjiang Hi-Tech Park, a major hub for life sciences innovation in China, featuring modern laboratory and office spaces.
Emphasis on scientific innovation, collaboration, speed, and a patient-centric approach. A dynamic and fast-paced environment driven by a global team.
Strategic location in one of China's leading biopharmaceutical ecosystems, facilitating R&D, talent acquisition, and access to the rapidly growing Chinese healthcare market.
Zai Lab operates globally with a strong footprint in China and the United States. Their functions supported globally include research and development, clinical trial management, regulatory affairs, manufacturing, and commercialization. They actively collaborate with international partners to advance their pipeline and bring therapies to patients worldwide, with a strategic emphasis on bridging innovation between China and the rest of the world.
Building 1, 4560 Jinke Road, Zhangjiang Hi-Tech Park, Pudong
Shanghai
Shanghai
China
Address: 215 First Street, Suite 400, Cambridge, MA 02142, USA
Access to the Boston/Cambridge biotech ecosystem, a global center for pharmaceutical innovation, talent, and investment. Drives global drug development and strategic alliances.
Address: South San Francisco (Specific address may vary, often for BD/Clinical roles)
Proximity to another major U.S. biotech hub, facilitating partnerships, talent acquisition, and engagement with the West Coast life sciences community.
Address: Office in Chaoyang District (Specific address may vary)
Strategic presence in China's capital for government relations, market access, and policy engagement relevant to the pharmaceutical industry.
Address: Suzhou BioBay or similar industrial park (Details on specific manufacturing site)
Key manufacturing hub ensuring quality production and supply chain management for therapies targeting the Chinese and potentially global markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Zai Lab' leadership includes:
Zai Lab has been backed by several prominent investors over the years, including:
Zai Lab has seen strategic appointments to strengthen its leadership team, particularly in R&D and operational roles, to support its expanding pipeline and global growth.
Discover the tools Zai Lab uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Zai Lab primarily uses the 'first.last@zailaboratory.com' email format. Variations might exist but this is the most common.
first.last@zailaboratory.com
Format
jane.doe@zailaboratory.com
Example
90%
Success rate
Zai Lab Press Release • 2024-05-28
Zai Lab's partner, Karuna Therapeutics, announced the FDA's acceptance of its New Drug Application (NDA) for KarXT (xanomeline-trospium) for schizophrenia treatment. Zai Lab has exclusive rights to develop, manufacture, and commercialize KarXT in Greater China....more
Zai Lab Press Release • 2024-05-08
Zai Lab reported its Q1 2024 financial results, highlighting product revenue growth driven by key commercial products like ZEJULA and VYVGART. The company also provided updates on its pipeline progress and strategic priorities for the year....more
Zai Lab Press Release • 2024-03-20
Zai Lab announced that China's NMPA approved VYVGART Hytrulo for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. This marks a significant milestone for patients in China....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Zai Lab, are just a search away.